Asian Pacific Journal of Cancer Prevention · 2013 · 62 citations · 27 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyAdjuvant ChemotherapyAdjuvant TherapyBreast Cancer PharmacotherapyMetastatic Breast CancerMetastatic Cancer ManagementMetastatic Disease TreatmentAnthracycline-based ChemotherapyBreast Cancer ChemotherapyMetastatic Breast Cancer TreatmentPartial Response AssessmentPhase Ii InvestigationStable Disease AssessmentStudy PhaseTaxane-based Chemotherapy
PURPOSE: This phase II study was undertaken to determine the efficacy and safety of Loubo® (Lobaplatin) in combination with pemetrexed in treating patients with metastatic breast cancer who failed to respond to anthracycline or taxanes. PATIENTS AND METHODS: Metastatic breast cancer cases who had previously received an anthracycline and a taxane in either adjuvant or metastatic settings, were enrolled. All patients were recruited from Jiangsu Cancer Hospital and Research Institute, and were treated with Loubo® (Lobaplatin) 35 mg/m2 (intravenous; on day 1) and pemetrexed 500 mg/m2 (intravenous; on day 1) every 21 days. Efficacy and side effects were evaluated after at least two cycles of chemotherapy. RESULTS: All eligible 19 patients completed at least 2 cycles of chemotherapy with pemetrexed and lobaplatin, and were evaluable. Overall, 3 (15.8%) patients achieved partial response, 11 (57.9%) stable disease, 5 (26.3%) progression of disease, with no complete remission. Response rate was 15.8%, disease control rate was 42.1%. The median survival time was 10.3 months. Neutrophil suppression occurred in 36.8% of patients who had grade 2 toxicity, and 26.3% had grade 3, 26.4% had grade 4. Thrombocytopenia was encountered as follows: 21.1% grade 2, 15.8% grade 3 and 5.5% grade 4. Incidences of anemia were 10.5% in grade 2, 5.3% grade 3 and 0% grade 4. Only 5.3% of patients required packed red blood cell transfusion. Grade 3 digestive tract toxicity occurred in 5.5% of patients. Other toxicities included elevated transaminase, oral mucositis and skin rashes. CONCLUSIONS: The regimen of lobaplatin and pemetrexed is modestly active in metastatic breast cancer patients who failed anthracycline or taxanes, and the toxicity profile suggesting that the doses of chemotherapy should be further modified.
27
Adjuvant Docetaxel for Node-Positive Breast Cancer
Miguel Martín, Tadeusz Pieńkowski, John R. Mackey et al. · New England Journal of Medicine · 2005 · 952 citations · Full text
Medicine, Oncology, Pharmacology +13